CTCF Antibody (sample size)

Catalog Number
10 μg
  Bulk order
Other format

Alternative name: MRD21

Polyclonal antibody raised in rabbit against human CTCF (CCCTC-Binding Factor), using 4 KLH coupled peptides.

New! The antibody has been validated in CUT&Tag - the validation data will be updated soon.

Concentration2.3 µg/µl
Species reactivityHuman, mouse: positive
TypePolyclonal ChIP-seq Grade
PurityAffinity purified
Storage ConditionsStore at -20°C; for long storage, store at -80°C. Avoid multiple freeze-thaw cycles.
Storage BufferPBS containing 0.05% azide and 0.05% ProClin 300.
PrecautionsThis product is for research use only. Not for use in diagnostic or therapeutic procedures.
Applications Suggested dilution References
ChIP/ChIP-seq * 2-5 µg per ChIP Fig 1, 2
ELISA 1:1,000 Fig 3
Western Blotting 1:1,000 Fig 4, 5
Immunofluorescence 1:500 Fig 6

* Please note that the optimal antibody amount per IP should be determined by the end-user. We recommend testing 1-10 µg per IP.

  • Validation Data

    CTCF Antibody ChIP Grade

    Figure 1. ChIP results obtained with the Diagenode antibody directed against CTCF
    ChIP was performed with the Diagenode antibody against CTCF (Cat. No. C15410210) on sheared chromatin from 4,000,000 HeLa cells. A titration consisting of 1, 2, 5 and 10 µg of antibody per ChIP experiment was analyzed. IgG (2 µg/IP) was used as a negative IP control. Quantitative PCR was performed with optimized primers for the H19 imprinting control region, and a specific region in the GAPDH gene, used as positive controls, and for the Sat2 satellite repeat region, used as a negative control. Figure 1 shows the recovery, expressed as a % of input (the relative amount of immunoprecipitated DNA compared to input DNA after qPCR analysis).

    A.CTCF Antibody ChIP-seq Grade

    B.CTCF Antibody for ChIP-seq

    C.CTCF Antibody for ChIP-seq assay

    D.CTCF Antibody validated in ChIP-seq

    Figure 2. ChIP-seq results obtained with the Diagenode antibody directed against CTCF
    ChIP was performed on sheared chromatin from 4,000,000 HeLa cells using 2 µg of the Diagenode antibody against CTCF (Cat. No. C15410210) as described above. The IP’d DNA was subsequently analysed on an Illumina HiSeq2000. Library preparation, cluster generation and sequencing were performed according to the manufacturer’s instructions. The 50 bp tags were aligned to the human genome using the BWA algorithm. Figure 2 shows the peak distribution along the complete sequence and a 1 mb region of chromosome 2 (figure 2A and B) and in two regions surrounding the H19 and GAPDH positive control genes, respectively (figure 2C and D).

    CTCF Antibody ELISA validation

    Figure 3. Determination of the antibody titer
    To determine the titer of the antibody, an ELISA was performed using a serial dilution of the Diagenode antibody against CTCF (Cat. No. C15410210). The plates were coated with the peptides used for immunization of the rabbit. By plotting the absorbance against the antibody dilution (Figure 3), the titer of the antibody was estimated to be 1:99,500.

    CTCF Antibody for Western Blot

    Figure 4. Western blot analysis using the Diagenode antibody directed against CTCF
    Whole cell extracts (25 µg) from HeLa cells were analysed by Western blot using the Diagenode antibody against CTCF (Cat. No. C15410210) diluted 1:1,000 in TBS-Tween containing 5% skimmed milk. The position of the protein of interest is indicated on the right; the marker (in kDa) is shown on the left.

    CTCF Antibody validated in  Western blot

    Figure 5. Western blot analysis using the Diagenode antibody directed against CTCF
    Whole cell extracts (40 µg) from HeLa cells transfected with CTCF siRNA (lane 2) and from an untransfected control (lane 1) were analysed by Western blot using the Diagenode antibody against CTCF (Cat. No. C15410210) diluted 1:1,000 in TBS-Tween containing 5% skimmed milk. The position of the protein of interest is indicated on the right; the marker (in kDa) is shown on the left.

    CTCF Antibody validated for Immunofluorescence

    Figure 6. Immunofluorescence using the Diagenode antibody directed against CTCF
    HeLa cells were stained with the Diagenode antibody against CTCF (Cat. No. C15410210) and with DAPI. Cells were fixed with 4% formaldehyde for 10’ and blocked with PBS/TX-100 containing 5% normal goat serum and 1% BSA. The cells were immunofluorescently labeled with the CTCF antibody (left) diluted 1:500 in blocking solution followed by an anti-rabbit antibody conjugated to Alexa488. The middle panel shows staining of the nuclei with DAPI. A merge of the two stainings is shown on the right.

  • Target Description

    CTCF (UniProt/Swiss-Prot entry P49711) is a transcriptional regulator protein with 11 highly conserved zinc finger domains. By using different combinations of the zinc finger domains, CTCF can bind to different DNA sequences and proteins. As such it can act as both a transcriptional repressor and a transcriptional activator. By binding to transcriptional insulator elements, CTCF can also block communication between enhancers and upstream promoters, thereby regulating imprinted gene expression. CTCF also binds to the H19 imprinting control region and mediates maternally inherited higher-order chromatin conformation to restrict enhancer access to IGF2. Mutations in the CTCF gene have been associated with invasive breast cancers, prostate cancers, and Wilms’ tumor.

  •  Testimonials

    In life sciences, epigenetics is nowadays the most rapid developing field with new astonishing discoveries made every day. To keep pace with this field, we are in need of reliable tools to foster our research - tools Diagenode provides us with. From antibodies to automated solutions - all from one source and with robust support. Antibodies used in our lab: H3K27me3 polyclonal antibody – Premium, H3K4me3 polyclonal antibody – Premium, H3K9me3 polyclonal antibody – Premium, H3K4me1 polyclonal antibody – Premium, CTCF polyclonal antibody – Classic, Rabbit IgG.

    Dr. Florian Uhle, Dept. of Anesthesiology, Heidelberg University Hospital, Germany
  •  Applications
    Western blot : The quality of antibodies used in this technique is crucial for correct and specific protein identification. Diagenode offers huge selection of highly sensitive and specific western blot-validated antibodies. Learn more about: Load... Read more
    Enzyme-linked immunosorbent assay. Read more
    ChIP-seq (ab)
    Read more
    ChIP-qPCR (ab)
    Read more
    Immunofluorescence: Diagenode offers huge selection of highly sensitive antibodies validated in IF. Immunofluorescence using the Diagenode monoclonal antibody directed against CRISPR/Cas9 HeLa cells transfected with a Cas9 expression vector (... Read more
    siRNA Knockdown
    Epigenetic antibodies you can trust! Antibody quality is essential for assay success. Diagenode offers antibodies that are actually validated and have been widely used and published by the scientific community. Now we are adding a new level o... Read more
  •  Documents
    Datasheet CTCF C15410210 DATASHEET
    Datasheet description
    Antibodies you can trust POSTER
    Epigenetic research tools have evolved over time from endpoint PCR to qPCR to the analyses of lar...
    Epigenetic Antibodies Brochure BROCHURE
    More than in any other immuoprecipitation assays, quality antibodies are critical tools in many e...
  •  Safety sheets
    CTCF polyclonal antibody SDS GB en Download
    CTCF polyclonal antibody SDS US en Download
    CTCF polyclonal antibody SDS DE de Download
    CTCF polyclonal antibody SDS JP ja Download
    CTCF polyclonal antibody SDS BE nl Download
    CTCF polyclonal antibody SDS BE fr Download
    CTCF polyclonal antibody SDS FR fr Download
    CTCF polyclonal antibody SDS ES es Download
  •  Publications

    How to properly cite this product in your work

    Diagenode strongly recommends using this: CTCF Antibody (sample size) (Diagenode Cat# C15410210-10 Lot# A2354-0010). Click here to copy to clipboard.

    Using our products in your publication? Let us know!

    ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma
    Babikir, H., Wang, L., Shamardani, K. et al.
    Background Recent single-cell transcriptomic studies report that IDH-mutant gliomas share a common hierarchy of cellular phenotypes, independent of genetic subtype. However, the genetic differences between IDH-mutant glioma subtypes are prognostic, predictive of response to chemotherapy, and correlate with distin...

    Integrative Omics Analyses Reveal Epigenetic Memory in Diabetic Renal CellsRegulating Genes Associated With Kidney Dysfunction.
    Bansal, A and Balasubramanian, S and Dhawan, S and Leung, A and Chen, Z andNatarajan, R
    Diabetic kidney disease (DKD) is a major complication of diabetes and the leading cause of end-stage renal failure. Epigenetics has been associated with metabolic memory, in which prior periods of hyperglycemia enhance the future risk of developing DKD despite subsequent glycemic control. To understand the mechanist...

    Preformed chromatin topology assists transcriptional robustness of during limb development.
    Paliou C, Guckelberger P, Schöpflin R, Heinrich V, Esposito A, Chiariello AM, Bianco S, Annunziatella C, Helmuth J, Haas S, Jerković I, Brieske N, Wittler L, Timmermann B, Nicodemi M, Vingron M, Mundlos S, Andrey G
    Long-range gene regulation involves physical proximity between enhancers and promoters to generate precise patterns of gene expression in space and time. However, in some cases, proximity coincides with gene activation, whereas, in others, preformed topologies already exist before activation. In this study, we inves...

    High-throughput ChIPmentation: freely scalable, single day ChIPseq data generation from very low cell-numbers.
    Gustafsson C, De Paepe A, Schmidl C, Månsson R
    BACKGROUND: Chromatin immunoprecipitation coupled to sequencing (ChIP-seq) is widely used to map histone modifications and transcription factor binding on a genome-wide level. RESULTS: We present high-throughput ChIPmentation (HT-ChIPmentation) that eliminates the need for DNA purification prior to library amplifica...

    DNA methylation signatures follow preformed chromatin compartments in cardiac myocytes
    Nothjunge S. et al.
    Storage of chromatin in restricted nuclear space requires dense packing while ensuring DNA accessibility. Thus, different layers of chromatin organization and epigenetic control mechanisms exist. Genome-wide chromatin interaction maps revealed large interaction domains (TADs) and higher order A and B compartments, r...

    High Resolution Mapping of Chromatin Conformation in Cardiac Myocytes Reveals Structural Remodeling of the Epigenome in Heart Failure
    Rosa-Garrido M. et al.
    Background -Cardiovascular disease is associated with epigenomic changes in the heart, however the endogenous structure of cardiac myocyte chromatin has never been determined. Methods -To investigate the mechanisms of epigenomic function in the heart, genome-wide chromatin conformation capture (Hi-C) and DNA sequenc...

    Platelet function is modified by common sequence variation in megakaryocyte super enhancers
    Petersen R. et al.
    Linking non-coding genetic variants associated with the risk of diseases or disease-relevant traits to target genes is a crucial step to realize GWAS potential in the introduction of precision medicine. Here we set out to determine the mechanisms underpinning variant association with platelet quantitative traits usi...

    Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma
    Shen CH et al.
    The protein kinase B-Raf proto-oncogene, serine/threonine kinase (BRAF) is an oncogenic driver and therapeutic target in melanoma. Inhibitors of BRAF (BRAFi) have shown high response rates and extended survival in patients with melanoma who bear tumors that express mutations encoding BRAF proteins mutant at Val600, ...

  •  Related products


 See all events


 See all news

The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.


       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics